Intranasal drug delivery for treatment of Alzheimer's disease

被引：70

作者：

Fonseca, Leonor C. ^{[1
,2
]}

Lopes, Joao A. ^{[1
,2
]}

Vieira, Joao ^{[1
,2
]}

Viegas, Claudia ^{[1
,2
]}

Oliveira, Claudia S. ^{[1
,2
]}

Hartmann, Rafael P. ^{[1
,2
]}

Fonte, Pedro ^{[1
,2
,3
]}

机构：

[1] Univ Algarve, Ctr Marine Sci CCMar, Gambelas Campus, P-8005139 Faro, Portugal

[2] Univ Algarve, Fac Sci & Technol, Dept Chem & Pharm, Gambelas Campus, P-8005139 Faro, Portugal

[3] Univ Lisbon, IBB Inst Bioengn & Biosci, Inst Super Tecn, Dept Bioengn, P-1049001 Lisbon, Portugal

来源：

DRUG DELIVERY AND TRANSLATIONAL RESEARCH | 2021年 / 11卷 / 02期

关键词：

Nanoparticle; Protein; Permeation enhancer; Blood-brain barrier; Central nervous system; Neurodegenerative; AMYLOID-BETA PEPTIDE; BRAIN DELIVERY; NASAL ABSORPTION; MOUSE MODEL; NANOPARTICLES; NOSE; TRANSPORT; MEMORY; PHARMACOLOGY; MANAGEMENT;

D O I：

10.1007/s13346-021-00940-7

中图分类号：

TH7 [仪器、仪表];

学科分类号：

0804 ; 080401 ; 081102 ;

摘要：

The Alzheimer's disease is a neurodegenerative condition with severe consequences interfering with patient quality of life. It is characterized as a progressive and irreversible brain disorder hampering memory and thinking, affecting the capacity to perform daily tasks leading to physical and cognitive incapacitation. The conventional treatment occurs by the oral route, but it presents relevant drawbacks such as low bioavailability, fast metabolism, limited brain exposure, and undesirable side effects. The intranasal route has been proposed as a promising alternative to deliver drugs and improve the Alzheimer's disease treatment. Still, there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety. The aim of this review is to perform an overview on the strategies for drug intranasal delivery for Alzheimer's disease treatment. The advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed. A special focus is given on the use of permeation enhancers, the types of intranasal drug delivery devices, as well as possible toxicity concerns.

引用

页码：411 / 425

页数：15

共 92 条

[51] CLINICAL-PHARMACOLOGY - PLASMA-PROTEIN BINDING OF DRUGS [J].